Evidence in Medicine. Iain K. Crombie
Читать онлайн книгу.
trials between 1975 and 2014. J. Clin. Epidemiol. 102: 123–128.
87 87. Colquhoun, D. (2014). An investigation of the false discovery rate and the misinterpretation of p‐values. R. Soc. Open Sci. https://doi.org/10.1098/rsos.140216.
88 88. IntHout, J., Ioannidis, J.P., Borm, G.F. et al. (2015). Small studies are more heterogeneous than large ones: a meta‐meta‐analysis. J. Clin. Epidemiol. 68: 860–869.
89 89. Froud, R., Rajendran, D., Patel, S. et al. (2017). The power of low Back pain trials: a systematic review of power, sample size, and reporting of sample size calculations over time, in trials published between 1980 and 2012. Spine 42: E680–E686.
90 90. Azad, T.D., Veeravagu, A., Mittal, V. et al. (2018). Neurosurgical randomized controlled trials‐distance travelled. Neurosurgery 82: 604–612.
91 91. Gan, H.K., You, B., Pond, G.R. et al. (2012). Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J. Natl. Cancer Inst. 104: 590–598.
92 92. Matheson, A. (2017). Marketing trials, marketing tricks – how to spot them and how to stop them. Trials https://doi.org/10.1186/s13063‐017‐1827‐5.
93 93. Lundh, A., Lexchin, J., Mintzes, B. et al. (2018). Industry sponsorship and research outcome: systematic review with meta‐analysis. Intensive Care Med. 44: 1603–1612.
94 94. Riaz, H., Raza, S., Khan, M.S. et al. (2015). Impact of funding source on clinical trial results including cardiovascular outcome trials. Am. J. Cardiol. 116: 1944–1947.
95 95. Sismondo, S. (2008). Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp. Clin. Trials 29: 109–113.
96 96. Sturmberg, J.P. (2019). From probability to believability. J. Eval. Clin. Pract. 26: 1081–1086.
97 97. Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. https://doi.org/10.1371/journal.pmed.0020138.
98 98. Pyke, S., Julious, S.A., Day, S. et al. (2011). The potential for bias in reporting of industry‐sponsored clinical trials. Pharm. Stat. 10: 74–79.
99 99. Zwierzyna, M., Davies, M., Hingorani, A.D. et al. (2018). Clinical trial design and dissemination: comprehensive analysis of http://clinicaltrials.gov and PubMed data since 2005. BMJ https://doi.org/10.1136/bmj.k2130.
100 100. Rasmussen, K., Bero, L., Redberg, R. et al. (2018). Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ https://doi.org/10.1136/bmj.k3654.
101 101. Lexchin, J. (2012). Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci. Eng. Ethics 18: 247–261.
102 102. Dunn, A.G., Bourgeois, F.T., and Coiera, E. (2013). Industry influence in evidence production. J. Epidemiol. Community Health 67: 537–538.
103 103. Every‐Palmer, S. and Howick, J. (2014). How evidence‐based medicine is failing due to biased trials and selective publication. J. Eval. Clin. Pract. 20: 908–914.
104 104. Flacco, M.E., Manzoli, L., Boccia, S. et al. (2015). Head‐to‐head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J. Clin. Epidemiol. 68: 811–820.
105 105. Spielmans, G.I. and Parry, P.I. (2010). From evidence‐based medicine to marketing‐based medicine: evidence from internal industry documents. J. Bioethic Inquiry 7: 13–29.
106 106. Ioannidis, J.P.A. (2018). Randomized controlled trials: often flawed, mostly useless, clearly indispensable: a commentary on Deaton and cartwright. Soc. Sci. Med. 210: 53–56.
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.